Please login to the form below

Not currently logged in
Email:
Password:

Hospira

This page shows the latest Hospira news and features for those working in and with pharma, biotech and healthcare.

Pfizer could raise ‘up to $15bn’ from consumer unit sale

Pfizer could raise ‘up to $15bn’ from consumer unit sale

of failed merger attempts with AstraZeneca and Allergan, the takeovers of Hospira and cancer specialist Medivation, and the divestment of Hospira’s infusions unit.

Latest news

More from news
Approximately 12 fully matching, plus 66 partially matching documents found.

Latest Intelligence

  • Innovation in merger control and the impact on the pharmaceutical sector Innovation in merger control and the impact on the pharmaceutical sector

    For example, in the Pfizer/Hospira merger, the Commission found that the proposed transaction raised competition concerns because Pfizer was developing a competing medicine to Hospira’s. ... Specifically, Hospira was selling Inflectra, an infliximab

  • Deal Watch October 2016 Deal Watch October 2016

    These two biosimilars were originally licensed by Hospira but when Pfizer acquired Hospira it terminated the agreement. ... For example in Europe both Pfizer (Hospira) in 2009 and Mundipharma in 2014 have rights to Celltrion's infliximab.

  • Biosimilars - the same, but different? Biosimilars - the same, but different?

    This first infliximab biosimilar was developed and manufactured by Celltrion and is marketed by various partners, notably Hospira under the brand name Inflectra and Mundipharma as Remsima.

  • Medius Deal Watch table for February 2015 Medius Deal Watch table for February 2015

    The top major pharma mergers, acquisitions and collaborations during the month were led by the Pfizer/Hospira and Salix/Valeant deals. ... Majority acquisition. 380. Pfenex/ Hospira. PF582 -  LUCENTIS biosimilar candidate - wet age-related macular

  • Pharma deals in February 2015 Pharma deals in February 2015

    There are no approved biosimilars in the US where Hospira awaits approval of Remicade and Retacrit. ... No doubt Pfizer had hoped Hospira's persistent manufacturing problems were a thing of the past.

More from intelligence
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Novasecta

We are a specialist strategy consulting firm for pharmaceutical and biotech companies. We help our clients to achieve significant performance...

Latest intelligence

The Exhibition Hall: Past, Present and Future
As I sit here at another pharma conference, I start to reflect on how they have changed over the years....
Success breeds success
This week we received the exciting news that we have been shortlisted for the Times Business Awards 2019, Tunbridge Wells in the 'Best Business 1-25 Employees' category....
Turning learning into action: The challenge of behaviour change
...

Infographics